1. Home
  2. HL vs RDY Comparison

HL vs RDY Comparison

Compare HL & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hecla Mining Company

HL

Hecla Mining Company

HOLD

Current Price

$18.68

Market Cap

12.1B

ML Signal

HOLD

Logo Dr. Reddy's Laboratories Ltd

RDY

Dr. Reddy's Laboratories Ltd

HOLD

Current Price

$13.57

Market Cap

11.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HL
RDY
Founded
1891
1984
Country
United States
India
Employees
1865
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.1B
11.6B
IPO Year
N/A
2001

Fundamental Metrics

Financial Performance
Metric
HL
RDY
Price
$18.68
$13.57
Analyst Decision
Buy
Strong Buy
Analyst Count
8
1
Target Price
$21.13
$16.90
AVG Volume (30 Days)
10.4M
2.4M
Earning Date
05-05-2026
05-12-2026
Dividend Yield
0.09%
0.52%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.92
$7.72
Revenue Next Year
N/A
$3.50
P/E Ratio
$44.94
$18.67
Revenue Growth
N/A
N/A
52 Week Low
$4.82
$12.77
52 Week High
$34.17
$16.17

Technical Indicators

Market Signals
Indicator
HL
RDY
Relative Strength Index (RSI) 50.55 51.30
Support Level $16.53 $12.90
Resistance Level $20.87 $14.06
Average True Range (ATR) 0.78 0.24
MACD -0.00 0.03
Stochastic Oscillator 49.85 56.64

Price Performance

Historical Comparison
HL
RDY

About HL Hecla Mining Company

Hecla Mining Co produces and explores silver, gold, zinc, and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, and Casa Berardi. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada, the United States, and Mexico, and it derives a majority of its revenue from the United States.

About RDY Dr. Reddy's Laboratories Ltd

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Share on Social Networks: